This is a pilot study that will determine the endoscopic recurrence of Crohn's disease 12
months after curative, resective ileal or ileocolonic surgery in patients receiving
post-operative vedolizumab (Entyvio) or placebo. The investigators hypothesize that the
administration of post-operative vedolizumab will decrease the endoscopic recurrence of
Crohn's disease.